Publications by authors named "Antoni Ribas"

99Publications

Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells.

Nat Commun 2020 09 24;11(1):4830. Epub 2020 Sep 24.

Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-020-18376-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518429PMC
September 2020

Disparities in Cancer Prevention in the COVID-19 Era.

Cancer Prev Res (Phila) 2020 Sep 17. Epub 2020 Sep 17.

Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-20-0447DOI Listing
September 2020

Triple therapy for BRAF-mutated melanoma.

Authors:
Antoni Ribas

Lancet 2020 06;395(10240):1814-1815

Department of Medicine, Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA 90095-1782, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(20)31285-XDOI Listing
June 2020

Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles.

bioRxiv 2020 Apr 1. Epub 2020 Apr 1.

Department of Radiation Oncology, UCLA, CA, 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/2020.03.30.016931DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239055PMC
April 2020

Trying for a BRAF Slam Dunk.

Cancer Discov 2020 May;10(5):640-642

Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0231DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363198PMC
May 2020

Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis.

Cell Discov 2019 26;5:62. Epub 2019 Nov 26.

2Department of Molecular, Cellular, and Integrative Physiology, University of California Los Angeles, Los Angeles, CA 90095 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41421-019-0130-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877514PMC
November 2019

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in -Mutant Melanoma.

Clin Cancer Res 2020 01 15;26(1):46-53. Epub 2019 Nov 15.

Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia, and University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-4180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942621PMC
January 2020

Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.

Cell Rep 2019 10;29(3):573-588.e7

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Dermatology, University of California, San Francisco, San Francisco, CA 94115, USA; Department of Pathology, University of California, San Francisco, San Francisco, CA 94115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939448PMC
October 2019

Tumour-intrinsic resistance to immune checkpoint blockade.

Nat Rev Immunol 2020 01 30;20(1):25-39. Epub 2019 Sep 30.

Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41577-019-0218-4DOI Listing
January 2020

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Cell Stem Cell 2019 10 5;25(4):542-557.e9. Epub 2019 Sep 5.

Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2019.08.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018522PMC
October 2019

Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood.

Cell Rep 2019 09;28(10):2728-2738.e7

Division of Chemistry and Chemical Engineering, California Institute of Technology, 1200 East California Blvd., Pasadena, CA 91125, USA; Institute for Systems Biology, Seattle, WA 98109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.07.106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774618PMC
September 2019

Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance.

PLoS Comput Biol 2019 06 5;15(6):e1007034. Epub 2019 Jun 5.

Institute for Systems Biology, Seattle, Washington, United State of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pcbi.1007034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6576794PMC
June 2019

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

N Engl J Med 2019 08 4;381(7):626-636. Epub 2019 Jun 4.

From Institut Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Aix-Marseille University, Marseille (J.J.G.), and Assistance Publique-Hôpitaux de Paris Dermatology and Clinical Investigation Center, Unité 976, Université de Paris, Hôpital Saint-Louis, Paris (C.L.) - all in France; Moscow City Oncology Hospital, Moscow (D. Stroyakovskiy), and the Petrov Research Institute of Oncology, St. Petersburg (E.L.) - both in Russia; Przychodnia Lekarska Komed, Konin (B.K.), the University of Medical Sciences, Poznań (A.M.), and the Maria Skłodowska-Curie Institute-Oncology Center, Warsaw (P.R.) - all in Poland; the University Hospital Schleswig-Holstein, Kiel (A.H.), the Department of Dermatology, University of Tübingen, Tübingen (C.G.), University Hospital Essen, Essen (D. Schadendorf), and the German Cancer Consortium, Heidelberg (D. Schadendorf) - all in Germany; the Veneto Institute of Oncology, Padua (V.C.S.), and Papa Giovanni XXIII Hospital, Bergamo (M.M.) - both in Italy; the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer (J.S.), and Sackler Medical School, Tel Aviv University, Tel Aviv (J.S.) - both in Israel; Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine (I.B.); Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens (H.G.); the Netherlands Cancer Institute, Amsterdam (J.B.A.G.H.); Mount Vernon Cancer Centre, Northwood, United Kingdom (P.D.N.); the University of California, Los Angeles, Los Angeles (A.R.); the University of Texas M.D. Anderson Cancer Center, Houston (M.A.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (K.T.F.); Novartis Pharma, Basel, Switzerland (P.B.); Novartis Pharmaceuticals, East Hanover, NJ (M.T., E.G., M.V.); and the Melanoma Institute Australia, the University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904059DOI Listing
August 2019

Interleukin 32 expression in human melanoma.

J Transl Med 2019 04 5;17(1):113. Epub 2019 Apr 5.

Department of Surgery, University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-1862-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449995PMC
April 2019

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.

Cancer Immunol Immunother 2019 Jun 12;68(6):897-905. Epub 2019 Mar 12.

Laura and Issac Perlmutter Cancer Center, New York University School of Medicine, 522 First Avenue, New York, NY, 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02318-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531317PMC
June 2019

T cell antigen discovery via trogocytosis.

Nat Methods 2019 02 28;16(2):183-190. Epub 2019 Jan 28.

Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41592-018-0305-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719556PMC
February 2019

T cell antigen discovery via signaling and antigen-presenting bifunctional receptors.

Nat Methods 2019 02 28;16(2):191-198. Epub 2019 Jan 28.

Department of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41592-018-0304-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755906PMC
February 2019

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers.

Clin Cancer Res 2019 02 27;25(4):1233-1238. Epub 2018 Jul 27.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0762DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348141PMC
February 2019

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.

Cancer Discov 2018 08 13;8(8):935-943. Epub 2018 Jun 13.

Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-1178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076867PMC
August 2018

The new era of adjuvant therapies for melanoma.

Nat Rev Clin Oncol 2018 09;15(9):535-536

Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0048-5
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0048-5DOI Listing
September 2018

Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs.

J Control Release 2018 07 9;282:156-165. Epub 2018 May 9.

Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Department of Biomedical Engineering, Duke Univeristy, 101 Science Drive, PO Box 90281, 27708, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01683659183026
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2018.05.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082662PMC
July 2018

Anti-PD-1 antibody treatment for melanoma.

Lancet Oncol 2018 05;19(5):e219

Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30202-XDOI Listing
May 2018

Antigen Presentation Keeps Trending in Immunotherapy Resistance.

Clin Cancer Res 2018 07 19;24(14):3239-3241. Epub 2018 Apr 19.

Jonsson Comprehensive Cancer Center, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-0698DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050090PMC
July 2018

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.

Cancer Cell 2018 05 12;33(5):890-904.e5. Epub 2018 Apr 12.

Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Building 114, Los Angeles, CA 90095, USA; Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA; UCLA Metabolomics Center, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA; California NanoSystems Institute, UCLA, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.03.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953834PMC
May 2018

Cancer immunotherapy using checkpoint blockade.

Science 2018 03 22;359(6382):1350-1355. Epub 2018 Mar 22.

Department of Medicine, Ludwig Center and Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aar4060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391259PMC
March 2018

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

J Clin Oncol 2018 06 28;36(17):1668-1674. Epub 2017 Dec 28.

Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6270
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6270DOI Listing
June 2018

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Melanoma Res 2017 12;27(6):585-590

aDepartment of Internal Medicine, Advocate Medical Group - Oncology North, Park Ridge, Illinois bMelanoma Research Clinic, University of Colorado Cancer Center, Aurora, Colorado cDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia dDepartment of Hematology and Oncology, The University of Arizona Cancer Center, Tucson, Arizona eDepartment of Medicine, Washington University School of Medicine, St Louis, Missouri fDepartment of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee gDepartment of Surgery, Columbia University Medical Center, New York, New York hDepartment of Medical Oncology, Texas Oncology, Dallas, Texas iDepartment of Medicine, Jonsson Comprehensive Cancer Center at University of California jDepartment of Immuno-Oncology, The Angeles Clinic and Research Institute, Los Angeles kDepartment of Oncology, Moores Cancer Center, University of California, San Diego, La Jolla lGenentech Inc., South San Francisco, California mMid Ohio Oncology and Hematology Inc., Columbus, Ohio nDepartment of Melanoma, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC oDepartment of Pathology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania pDepartment of Melanoma, Carol G. Simon Cancer Center, Atlantic Health System, Morristown, New Jersey, USA.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00008390-201712000-0000
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000398DOI Listing
December 2017

Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.

Leuk Lymphoma 2018 08 23;59(8):1785-1796. Epub 2017 Oct 23.

b Department of Medicine , University of California at Los Angeles Jonsson Comprehensive Cancer Center , Los Angeles , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1387905DOI Listing
August 2018

Endocrinopathies with use of cancer immunotherapies.

Clin Endocrinol (Oxf) 2018 02 9;88(2):327-332. Epub 2017 Oct 9.

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cen.13483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771947PMC
February 2018

Collaborative Care in Melanoma: The Essential Role of the Nurse
.

Clin J Oncol Nurs 2017 08;21(4 Suppl):4-6

University of California, Los Angeles Jonsson Comprehensive Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/17.CJON.S4.4-6DOI Listing
August 2017

SnapShot: Immune Checkpoint Inhibitors.

Cancer Cell 2017 06;31(6):848-848.e1

Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.05.010DOI Listing
June 2017